CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 349 enrolled
Drug / intervention
Bupropion +3 moredrug
Likely dose
Not stated in record
Key inclusion· 3
  • ✓Smoke at least 10 cigarettes per day
  • ✓Report concern about cessation-related weight gain
  • ✓Motivated to quit smoking
Key exclusion· 9
  • ✕Pregnant, lactating, or lacking medically approved contraception
  • ✕Major medical problem
  • ✕History of seizure disorder or head injury
  • ✕Current or historical psychosis or bipolar disorder

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00006170
NCT00006170Phase 4Completed
CompareCT.gov

Bupropion and Weight Control for Smoking Cessation

University of Pittsburgh·interventional·Posted Aug 10, 2000·Updated Jul 21, 2016

In Brief

A Phase 4 clinical trial evaluating Bupropion, Placebo, and 2 other interventions for Tobacco Use Disorder. Completed, enrolled 349 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether the addition of bupropion (Zyban) to cognitive behavioral therapy (CBT) will enhance longer-term tobacco abstinence in women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTobacco Use Disorder
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 4CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 10, 2000
Enrollment StartSep 1, 2000
Primary CompletionDec 1, 2009
Study CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9.3 yearsPosted 25.9 years ago

Interventions

Bupropiondrug

smoking cessation medication aid

Placebodrug

A matched placebo pill

weight concerns interventionbehavioral

cognitive behavioral treatment to address weight concners

smoking cessation interventionbehavioral

Cognitive behavioral intervention for smoking cessation